Aldeyra Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ALDX

Core Viewpoint - Aldeyra Therapeutics, Inc. is facing a class action lawsuit for securities law violations, specifically for making false and misleading statements regarding its drug candidate reproxalap during clinical trials [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is from November 3, 2023, to March 16, 2026, with a deadline for participation set for May 29, 2026 [2]. - The complaint alleges that Aldeyra's positive statements about its clinical trials were unreliable and that the results of reproxalap were inconsistent [2]. Group 2: Investor Participation - Shareholders who purchased shares during the class period are encouraged to contact the DJS Law Group for potential lead plaintiff appointments, although such an appointment is not necessary to recover losses [2][3].